OPKO Health, Inc.
OPKO Health, Inc. (0KCS.L) Financial Performance & Income Statement Overview
Explore the financials of OPKO Health, Inc. (0KCS.L), including yearly and quarterly data on income, cash flow, and balance sheets.
OPKO Health, Inc. (0KCS.L) Income Statement & Financial Overview
Review OPKO Health, Inc. 0KCS.L income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $149.95M | $183.64M | $173.63M | $182.19M |
| Cost of Revenue | $107.33M | $98.98M | $133.50M | $130.53M |
| Gross Profit | $42.62M | $84.66M | $40.13M | $51.65M |
| Gross Profit Ratio | $0.28 | $0.46 | $0.23 | $0.28 |
| R&D Expenses | $30.84M | $30.43M | $28.77M | $24.08M |
| SG&A Expenses | $59.09M | $67.03M | $98.20M | $68.82M |
| Operating Expenses | $109.79M | $117.80M | $25.91M | $113.32M |
| Total Costs & Expenses | $217.12M | $216.78M | $235.82M | $243.86M |
| Interest Income | $4.68M | $4.29M | $2.93M | $391000.00 |
| Interest Expense | $15.47M | $14.24M | $17.36M | $8.18M |
| Depreciation & Amortization | $23.49M | $24.04M | $24.16M | $24.16M |
| EBITDA | -$34.42M | $73.18M | $89.94M | $21.75M |
| EBITDA Ratio | -$0.23 | $0.40 | $0.52 | $0.12 |
| Operating Income | -$67.17M | -$33.14M | $14.22M | -$61.67M |
| Operating Income Ratio | -$0.45 | -$0.18 | $0.08 | -$0.34 |
| Other Income/Expenses (Net) | -$6.21M | $68.12M | $34.20M | $51.09M |
| Income Before Tax | -$73.37M | $34.98M | $48.42M | -$10.58M |
| Income Before Tax Ratio | -$0.49 | $0.19 | $0.28 | -$0.06 |
| Income Tax Expense | -$5.76M | $20.90M | $23.53M | -$280000.00 |
| Net Income | -$67.61M | $14.03M | $24.89M | -$10.30M |
| Net Income Ratio | -$0.45 | $0.08 | $0.14 | -$0.06 |
| EPS | -$0.10 | $0.02 | $0.04 | -$0.01 |
| Diluted EPS | -$0.10 | $0.02 | $0.02 | -$0.01 |
| Weighted Avg Shares Outstanding | $671.58M | $797.44M | $694.62M | $697.21M |
| Weighted Avg Shares Outstanding (Diluted) | $671.58M | $694.02M | $695.62M | $697.21M |
The company's financials show resilient growth, with revenue advancing from $182.19M in Q2 2024 to $149.95M in Q1 2025. Gross profit remained healthy with margins at 28% in Q1 2025 compared to 28% in Q2 2024. Operating income hit -$67.17M last quarter, sustaining a consistent -45% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$34.42M. Net income dropped to -$67.61M, while earnings per share reached -$0.10. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan